Sionna Therapeutics, Inc. $SION Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its stake in Sionna Therapeutics, Inc. (NASDAQ:SION) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,978,626 shares of the company’s stock after selling 242,562 shares during the period. JPMorgan Chase & Co.’s holdings in Sionna Therapeutics were worth $58,191,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics during the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics in the 2nd quarter worth approximately $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Sionna Therapeutics in the second quarter valued at approximately $45,000. Virtus Investment Advisers LLC purchased a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $117,000.

Sionna Therapeutics Stock Up 3.2%

Shares of SION opened at $35.49 on Friday. The firm has a market cap of $1.60 billion and a price-to-earnings ratio of -18.20. The business’s 50 day moving average is $38.23 and its two-hundred day moving average is $36.19. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SION. Guggenheim upped their target price on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a research report on Monday, December 1st. Finally, Citizens Jmp started coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.57.

Insider Buying and Selling at Sionna Therapeutics

In other Sionna Therapeutics news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the transaction, the insider directly owned 6,494,962 shares of the company’s stock, valued at $259,798,480. This trade represents a 3.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Peter A. Thompson sold 33,356 shares of the business’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the sale, the director directly owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. The trade was a 0.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 378,618 shares of company stock worth $15,731,751 in the last ninety days. 3.90% of the stock is owned by insiders.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.